COGTCogent Biosciences, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−14% vs 200-day) and heavily shorted (+11% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −14% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How COGT is trading
Cogent Biosciences, Inc. is +159% over the past year while the S&P 500 is +18%: 141 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −14%
vs 200-day average · a clear downtrend
- RSI (14)
- 43
RSI (14) · neutral
- Below its 52-week high
- 28%
Below its 52-week high
Details›
- Last close2026-10-09
- $31.02
- 1 monthS&P 500 +2.7%
- −9.0%
- 1 yearS&P 500 +18%
- +159%
- 5 yearsS&P 500 +88%
- +286%
- vs 50-day average$35.14
- −12%
- 52-week high
- $42.84
- 52-week low
- $12.51
- Annualised volatility
- 103%
| Year | Return |
|---|---|
| 2026 (year to date) | −13% |
| 2025 | +355% |
| 2024 | +33% |
| 2023 | −49% |
| 2022 | +35% |
| 2021 | −24% |
| 2020 | +290% |
| 2019 | −84% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 4 of 8 | −1.0% |
| Feb | 8 | 2 of 8 | −0.88% |
| Mar | 8 | 3 of 8 | −5.1% |
| Apr | 9 | 2 of 9 | −6.4% |
| May | 9 | 5 of 9 | +4.5% |
| Jun | 9 | 6 of 9 | +13% |
| Jul | 9 | 7 of 9 | +62% |
| Aug | 9 | 5 of 9 | +9.7% |
| Sep | 9 | 3 of 9 | −11% |
| Oct | 9 | 4 of 9 | −1.3% |
| Nov | 8 | 1 of 8 | +4.6% |
| Dec | 8 | 2 of 8 | −9.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.